02.09.12
BioMimetic Therapeutics Inc. introduces its Augmatrix biocomposite bone graft, a new bone graft substitute product line, during the American Academy of Orthopedic Surgeons (AAOS) meeting this week in San Francisco, Calif.
The Augmatrix product line is comprises carbonate-apatite (calcium phosphate) and Type I collagen, and is designed to be combined with bone marrow aspirate. The products are available in different forms to meet varied bone grafting challenges, including fracture repair and general bone void filling procedures. The product line has been cleared by the U.S. Food and Drug Administration for use in orthopedic indications and is ready for sale in the United States.
Aggregate sales of bone graft substitutes in the U.S. are estimated to reach $1.7 billion in 2012, according to Millennium Research.
“We believe the addition of the Augmatrix product line will provide surgeons with a range of bone grafting solutions to procedures for which our rhPDGF-BB based offerings will not initially be indicated,” said Samuel Lynch, president and CEO. “The Augmatrix bone graft substitute platform presents a perfect complement to our existing orthobiologic portfolio and will allow us to penetrate the large bone graft substitutes market earlier than anticipated."
Franklin, Tenn.-based BioMimetic specializes in products to promote the healing of musculoskeletal injuries and diseases, including therapies for orthopedics, sports medicine and spine applications. The firm’s Augment line of products are based upon recombinant human platelet-derived growth factor (rhPDGF-BB), which is an engineered form of PDGF, one of the body's principal agents to stimulate and direct healing and regeneration. BioMimetic line of regenerative medicine is intended to provide new treatment options for the repair of bone, cartilage, tendons and ligaments.
The company received regulatory approval in 2009 and 2011 to market Augment bone graft in Canada and in Australia for hindfoot and ankle fusion indications. Augment is pending regulatory decisions in the U.S. and European Union for similar indications.
The Augmatrix product line is comprises carbonate-apatite (calcium phosphate) and Type I collagen, and is designed to be combined with bone marrow aspirate. The products are available in different forms to meet varied bone grafting challenges, including fracture repair and general bone void filling procedures. The product line has been cleared by the U.S. Food and Drug Administration for use in orthopedic indications and is ready for sale in the United States.
Aggregate sales of bone graft substitutes in the U.S. are estimated to reach $1.7 billion in 2012, according to Millennium Research.
“We believe the addition of the Augmatrix product line will provide surgeons with a range of bone grafting solutions to procedures for which our rhPDGF-BB based offerings will not initially be indicated,” said Samuel Lynch, president and CEO. “The Augmatrix bone graft substitute platform presents a perfect complement to our existing orthobiologic portfolio and will allow us to penetrate the large bone graft substitutes market earlier than anticipated."
Franklin, Tenn.-based BioMimetic specializes in products to promote the healing of musculoskeletal injuries and diseases, including therapies for orthopedics, sports medicine and spine applications. The firm’s Augment line of products are based upon recombinant human platelet-derived growth factor (rhPDGF-BB), which is an engineered form of PDGF, one of the body's principal agents to stimulate and direct healing and regeneration. BioMimetic line of regenerative medicine is intended to provide new treatment options for the repair of bone, cartilage, tendons and ligaments.
The company received regulatory approval in 2009 and 2011 to market Augment bone graft in Canada and in Australia for hindfoot and ankle fusion indications. Augment is pending regulatory decisions in the U.S. and European Union for similar indications.